The Cooper Companies, Inc.
Rank #335HypergrowthCOO · Nasdaq · Healthcare
The Cooper Companies, Inc. (COO) — Rank #335 by gross profitability (GP/assets 0.21) · ROE 4.5% · Piotroski F-Score 5 / 9.
As-of 2026-09-15 · CIK 0000711404 · all metrics point-in-time as of the filing date.
About
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.
Show moreShow less
The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc.
was founded in 1958 and is headquartered in San Ramon, California.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- October 31
- Website
- coopercos.com
Segments
A revenue-by-segment breakdown is not available for COO. This is expected for a single-reportable-segment filer with no product/service revenue disaggregation, or for a company whose filings predate SEC’s XBRL viewer.